Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMTX705 + nab-paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- Oncomatryx
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
OMTX705 + nab-paclitaxel + gemcitabine is an investigational combination therapy being developed by Oncomatryx Biopharma S.L. for the treatment of advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). The regimen's novel component, OMTX705, is a first-in-class antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody targeting Fibroblast Activation Protein (FAP) conjugated to TAM470, a potent cytolysin payload that acts as a tubulin inhibitor. FAP is highly expressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment, which are known to create a physical and biochemical barrier against drug delivery and immune infiltration. By targeting CAFs, OMTX705 aims to disrupt the tumor stroma, while the standard-of-care chemotherapy doublet of nab-paclitaxel (an albumin-bound microtubule stabilizer) and gemcitabine (a nucleoside analog that inhibits DNA synthesis) directly targets the malignant epithelial cells. This dual-action approach is currently being evaluated in Phase 1b clinical trials, sometimes in further combination with the PD-1 inhibitor tislelizumab.
- Other names
- OMTX705 + gemcitabine + nab-paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on OMTX705 + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMTX705 + nab-paclitaxel + gemcitabine.